Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., Hu, Y., Luo, G., Wang, K., Lu, Y., Li, H., Wang, S., Ruan, S., Yang, C., Mei, C., Wang, Y., Ding, D., Wu, F., Tang, X., Ye, X., Ye, Y., Liu, B., Yang, J., Yin, W., Wang, A., Fan, G., Zhou, F., Liu, Z., Gu, X., Xu, J., Shang, L., Zhang, Y., Cao, L., Guo, T., Wan, Y., Qin, H., Jaki, T., Hayden, F., Horby, P., Cao, B. and Wang, C. (2020) Remdesivir in Adults with Severe COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial. The Lancet, 395, 1569-1578.
https://doi.org/10.1016/S0140-6736(20)31022-9

has been cited by the following article:

• TITLE: COVID-19 and Chronic Viral Liver Diseases

  AUTHORS: Maged Tharwat Elghannam, Motaz Hasan Hassanien, Yosry Abdelrahman, Gamalaldin Mohammed ALattar, Emad Abdelwahab Turky, Ahmed Aly EL Ray, Mohammed Darwish EL Talkawy

  KEYWORDS: COVID-19, Chronic Liver Disease, Cell Entry, Pathology, Pathogenesis and Pathophysiology, Impact on CLD

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.9 No.9, September 18, 2021

  ABSTRACT: Coronavirus causes an outbreak of viral pneumonia that spread throughout the world. Liver injury is becoming more widely recognized as a component of the clinical picture of COVID-19 infection. We aimed to review this relation in a concise way. This review article includes a large number of patients from both western and eastern countries with no clear difference of liver affection. The more severe and frequent liver injury, the more severe COVID-19 infection. Up to half of patients developed hepatitis with serum ALT elevation. Both hepatocellular and/or ductular injury were observed as evidenced by alkaline phosphatase elevation. Increase incidence of morbidity and mortality had been recorded in patients with CLD. Cirrhosis mortality extended in line with the Child-Turcotte-Pugh class. The incidence of ACLF in CLD patients with COVID 19 is not clear. There are no significant associations with the etiology of liver disease and death in cirrhosis. COVID-19 hinders HCV elimination by 2030. Patients should continue their medications if already receiving treatment. Patients with occult or resolved HBV and COVID-19 who are receiving immunosuppressive agents should use antiviral therapy to prevent viral flare-ups.